Let’s Talk: A Conversation with Professor Caicun Zhou
September 17, 2026
Lung cancer care has undergone one of the most dramatic transformations in modern oncology, moving from a landscape defined by limited treatment options and poor prognoses to one shaped by precision biomarker testing, targeted therapy, immunotherapy, and now next-generation bispecific antibodies redefining the standard of care.
In this webcast, Professor Caicun Zhou, Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2clinical trial for Ivonescimab versus pembrolizumab in NSCLC, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the evolution of lung cancer and China’s growing role in global oncology innovation.
Key topics discussed in this webcast:
Professor Zhou’s journey from pulmonologist to one of the world’s leading lung cancer oncologists and clinical trial leaders
The evolution of lung cancer treatment, from chemotherapy to targeted therapies and immunotherapy
The groundbreaking results from the HARMONi-2 study and the promise of PD-1-VEGF bispecific antibodies, including Ivonescimab
What is driving China’s rapid rise as a global force in oncology innovation
Why standardizing biomarker testing globally is essential to advancing precision medicine
CellCarta is excited to share this conversation between lung cancer treatment pioneer Professor Caicun Zhou and our Chief Scientific Business Officer Christopher Ung. We support clinical trials from discovery to translation and companion diagnostic development. If you are working on biomarker driven therapeutics or NSCLC, connect with our team to discover how we can help you accelerate your programs- from targeted genomic assays with rapid turn around times for genomic alterations (AGAs) to custom NGS assay development for your specific program needs.
About the Speakers:
Professor Caicun Zhou
Professor Caicun Zhou is the Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2i clinical trial. He joined the IASLC Board of Directors in 2019 and currently serves as President of the organization, the first from mainland China. With more than 20 years of experience in clinical oncology, Professor Zhou has focused his research on early detection, molecular targeted therapy, anti-angiogenesis therapy, and immunotherapy in lung cancer. Professor Zhou has published over 200 articles in international peer-reviewed journals, including The Lancet Oncology, The Lancet Respiratory Medicine, Journal of Clinical Oncology, and Annals of Oncology, and has authored three books on lung cancer. In 2002, he worked as a visiting scientist at the MD Anderson Cancer Center. He studied medicine at NanTong Medical College, earned his Ph.D. at China Medical University, and served as a fellow at Tokyo National Chest Hospital.
Christopher Ung
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and digital services.
Let’s Talk Webcasts
Our Webcast series features in-depth conversations with thought leaders in precision therapeutics. Join our speakers as they engage in insightful fireside chat-style discussions on a variety of topics in this dynamic space.
Let’s Talk: A Conversation with Professor Caicun Zhou
September 17, 2026
Lung cancer care has undergone one of the most dramatic transformations in modern oncology, moving from a landscape defined by limited treatment options and poor prognoses to one shaped by precision biomarker testing, targeted therapy, immunotherapy, and now next-generation bispecific antibodies redefining the standard of care.
In this webcast, Professor Caicun Zhou, Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2clinical trial for Ivonescimab versus pembrolizumab in NSCLC, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the evolution of lung cancer and China’s growing role in global oncology innovation.
Key topics discussed in this webcast:
Professor Zhou’s journey from pulmonologist to one of the world’s leading lung cancer oncologists and clinical trial leaders
The evolution of lung cancer treatment, from chemotherapy to targeted therapies and immunotherapy
The groundbreaking results from the HARMONi-2 study and the promise of PD-1-VEGF bispecific antibodies, including Ivonescimab
What is driving China’s rapid rise as a global force in oncology innovation
Why standardizing biomarker testing globally is essential to advancing precision medicine
CellCarta is excited to share this conversation between lung cancer treatment pioneer Professor Caicun Zhou and our Chief Scientific Business Officer Christopher Ung. We support clinical trials from discovery to translation and companion diagnostic development. If you are working on biomarker driven therapeutics or NSCLC, connect with our team to discover how we can help you accelerate your programs- from targeted genomic assays with rapid turn around times for genomic alterations (AGAs) to custom NGS assay development for your specific program needs.
About the Speakers:
Professor Caicun Zhou
Professor Caicun Zhou is the Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2i clinical trial. He joined the IASLC Board of Directors in 2019 and currently serves as President of the organization, the first from mainland China. With more than 20 years of experience in clinical oncology, Professor Zhou has focused his research on early detection, molecular targeted therapy, anti-angiogenesis therapy, and immunotherapy in lung cancer. Professor Zhou has published over 200 articles in international peer-reviewed journals, including The Lancet Oncology, The Lancet Respiratory Medicine, Journal of Clinical Oncology, and Annals of Oncology, and has authored three books on lung cancer. In 2002, he worked as a visiting scientist at the MD Anderson Cancer Center. He studied medicine at NanTong Medical College, earned his Ph.D. at China Medical University, and served as a fellow at Tokyo National Chest Hospital.
Christopher Ung
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and digital services.
Let’s Talk Webcasts
Our Webcast series features in-depth conversations with thought leaders in precision therapeutics. Join our speakers as they engage in insightful fireside chat-style discussions on a variety of topics in this dynamic space.
In this webcast, Dr. Thomas Powles, Chair of Barts Cancer Centre (UK), joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest on Antibody Drug Conjugates (ADCs) and other innovative cancer therapies.
Key topics discussed in this webcast:
The challenges of treating metastatic bladder cancer
Targeting metastatic bladder cancer with Nectin-4 ADC
New ways of thinking about biomarkers for ADCs
How spatial biology could improve ADC assessment
Bi-specifics and other innovative therapies for metastatic bladder cancer
Being a physician and running clinical trials
Dr. Powles is a renowned expert in urology cancer and drug development, serving as the Chair of the Barts Cancer Centre at St. Bartholomew’s Hospital, Queen Mary University of London. He leads numerous clinical trials across all phases. Notably, his work in bladder and renal cancer has been pivotal in establishing new immunotherapy and antibody drug conjugate treatments as standards of care globally. Dr. Powles has been included in TIME’s list of the 100 most influential people in global health and in the Nature10 list in 2023.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
Let's Talk: A Conversation with Dr. Thomas Powles
November 28, 2024
In this webcast, Dr. Thomas Powles, Chair of Barts Cancer Centre (UK), joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest on Antibody Drug Conjugates (ADCs) and other innovative cancer therapies.
Key topics discussed in this webcast:
The challenges of treating metastatic bladder cancer
Targeting metastatic bladder cancer with Nectin-4 ADC
New ways of thinking about biomarkers for ADCs
How spatial biology could improve ADC assessment
Bi-specifics and other innovative therapies for metastatic bladder cancer
Being a physician and running clinical trials
Dr. Powles is a renowned expert in urology cancer and drug development, serving as the Chair of the Barts Cancer Centre at St. Bartholomew’s Hospital, Queen Mary University of London. He leads numerous clinical trials across all phases. Notably, his work in bladder and renal cancer has been pivotal in establishing new immunotherapy and antibody drug conjugate treatments as standards of care globally. Dr. Powles has been included in TIME’s list of the 100 most influential people in global health and in the Nature10 list in 2023.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
Let's Talk: A Conversation with Dr. Scott Gottlieb
September 10, 2024
The drug development landscape is rapidly evolving, with new regulatory guidance, novel therapy types, and exciting AI-powered technologies altering the face of clinical testing.
In this webcast, Scott Gottlieb, former FDA commissioner, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest in regulatory and biomarker development.
Key topics discussed in this webcast:
The history and future of cell therapies
The FDA’s final rule to regulate lab-developed IVDs as medical devices
How to navigate the FDA’s new oncology IVD pilot program
T cell health in immune oncology and metabolic drug development
How AI-powered digital pathology is revolutionizing cell therapy development
Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improve medical outcomes, reshape healthcare delivery, and expand consumer choice and safety. He is currently a partner at the venture capital firm New Enterprise Associates; a resident fellow at the American Enterprise Institute; a contributor to CNBC; and a board member to Pfizer, Inc. and Illumina, Inc.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
Let's Talk: A Conversation with Dr. Scott Gottlieb
September 10, 2024
The drug development landscape is rapidly evolving, with new regulatory guidance, novel therapy types, and exciting AI-powered technologies altering the face of clinical testing.
In this webcast, Scott Gottlieb, former FDA commissioner, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest in regulatory and biomarker development.
Key topics discussed in this webcast:
The history and future of cell therapies
The FDA’s final rule to regulate lab-developed IVDs as medical devices
How to navigate the FDA’s new oncology IVD pilot program
T cell health in immune oncology and metabolic drug development
How AI-powered digital pathology is revolutionizing cell therapy development
Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improve medical outcomes, reshape healthcare delivery, and expand consumer choice and safety. He is currently a partner at the venture capital firm New Enterprise Associates; a resident fellow at the American Enterprise Institute; a contributor to CNBC; and a board member to Pfizer, Inc. and Illumina, Inc.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
Let's Talk: A Conversation with CAR T-cell Therapy Pioneer Dr. Carl June
February 22, 2024
Immunotherapies such as CAR T-cell therapy hold a lot of promise in treating illnesses like cancer. However, key challenges remain in their development, in particular the need to address adverse events and patient resistance.
In this webcast, Dr. Carl June, a pioneer in the field of CAR T-cell therapy, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on developing immuno and CAR T-cell therapies.
Key topics discussed in this cell therapy focused webcast:
Academic and Industry Partnership in CAR-T Development
CAR-T Development in US and China
Biomarkers from vein to vein: Mechanism, Selection, and Resistance
Facing the Challenges: Adverse Events and Patient Resistance
New Frontiers: Solid Tumors, Evolutionary and Revolutionary CAR models
Dr. Carl June
Dr. June is a member of CellCarta’s Scientific Advisory Board and the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.
In 2011, his research team published a paper on the first CAR-T therapy treating leukemia patients with their own genetically modified T-cells.
Mr. Christopher Ung
Mr. Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field.
Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumour and anatomic pathology services.
Let's Talk: A Conversation with CAR T-cell Therapy Pioneer Dr. Carl June
February 22, 2024
Immunotherapies such as CAR T-cell therapy hold a lot of promise in treating illnesses like cancer. However, key challenges remain in their development, in particular the need to address adverse events and patient resistance.
In this webcast, Dr. Carl June, a pioneer in the field of CAR T-cell therapy, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on developing immuno and CAR T-cell therapies.
Key topics discussed in this cell therapy focused webcast:
Academic and Industry Partnership in CAR-T Development
CAR-T Development in US and China
Biomarkers from vein to vein: Mechanism, Selection, and Resistance
Facing the Challenges: Adverse Events and Patient Resistance
New Frontiers: Solid Tumors, Evolutionary and Revolutionary CAR models
Dr. Carl June
Dr. June is a member of CellCarta’s Scientific Advisory Board and the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.
In 2011, his research team published a paper on the first CAR-T therapy treating leukemia patients with their own genetically modified T-cells.
Mr. Christopher Ung
Mr. Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field.
Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumour and anatomic pathology services.
Get a comprehensive overview of IVDR and explore the challenges encountered during the submission and approval process for clinical trial assays, including examples of feedback received from Member States and how to address them.
In this webinar, the team discusses the delegation of responsibilities to CROs by clinical trial sponsors, as well as the importance of performance study documentation to help clinical trial assays along the path to regulatory submission and approval.
Additionally, viewers gain insights into the classification of medical devices based on the rules outlined in Annex VIII of the IVDR.
Viewers will :
Gain valuable insights into the IVDR submission process
Be equipped with the knowledge and strategies required to overcome challenges, ensure compliance and streamline the path from assay development to successful submission
Learn how to properly navigate the IVDR landscape and ensure that clinical trial assays have the best chance of approval
Pamela Swatkowski, Vice President of Global Regulatory Affairs
Pamela Swatkowski has extensive leadership experience in regulatory affairs, quality assurance, business development, clinical and research and development in the medical device and IVD industry in the US food and Drug Administration (FDA)-regulated diagnostic industry leading US and international regulatory submissions and global compliance activities.
Her medical device experience includes: molecular infectious disease, oncology, companion diagnostics, single site IVD global approvals, NGS based immuo-sequencing, microbiology, genetics and immunology in vitro diagnostic assays and instruments, injection molded devices, peritoneal dialysis catheters and orthopedic spinal implants.
She was also the President and Founder of PLS Consulting, LLC. Pamela previously held leadership positions in quality, regulatory affairs and compliance positions at Abbott Molecular and Thermofisher. She has a degree in biology and chemistry from Loyola University of Chicago.
Get a comprehensive overview of IVDR and explore the challenges encountered during the submission and approval process for clinical trial assays, including examples of feedback received from Member States and how to address them.
In this webinar, the team discusses the delegation of responsibilities to CROs by clinical trial sponsors, as well as the importance of performance study documentation to help clinical trial assays along the path to regulatory submission and approval.
Additionally, viewers gain insights into the classification of medical devices based on the rules outlined in Annex VIII of the IVDR.
Viewers will :
Gain valuable insights into the IVDR submission process
Be equipped with the knowledge and strategies required to overcome challenges, ensure compliance and streamline the path from assay development to successful submission
Learn how to properly navigate the IVDR landscape and ensure that clinical trial assays have the best chance of approval
Pamela Swatkowski, Vice President of Global Regulatory Affairs
Pamela Swatkowski has extensive leadership experience in regulatory affairs, quality assurance, business development, clinical and research and development in the medical device and IVD industry in the US food and Drug Administration (FDA)-regulated diagnostic industry leading US and international regulatory submissions and global compliance activities.
Her medical device experience includes: molecular infectious disease, oncology, companion diagnostics, single site IVD global approvals, NGS based immuo-sequencing, microbiology, genetics and immunology in vitro diagnostic assays and instruments, injection molded devices, peritoneal dialysis catheters and orthopedic spinal implants.
She was also the President and Founder of PLS Consulting, LLC. Pamela previously held leadership positions in quality, regulatory affairs and compliance positions at Abbott Molecular and Thermofisher. She has a degree in biology and chemistry from Loyola University of Chicago.
